Global Neurology Clinical Trials Market Forecasted to Grow Steadily at 6.7% CAGR Between 2025 and 2029
Use Code ONLINE20 to Save 20% On Global Market Reports – Gain Access to Trusted Market Data, Growth Indicators, and Industry Analytics
What Is the Predicted Market Size and CAGR of the Neurology Clinical Trials Market by the End of the 2029?
The neurology clinical trials market size has grown strongly in recent years. It will grow from $5.42 billion in 2024 to $5.80 billion in 2025 at a compound annual growth rate (CAGR) of 7.0%. The growth in the historic period can be attributed to the increasing prevalence of neurological disorders, rising demand for innovative treatment options, the rise in the aging population, increasing investments in research and development by pharmaceutical companies, and rising awareness and diagnosis rates for neurological conditions.
The neurology clinical trials market size is expected to see strong growth in the next few years. It will grow to $7.54 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to growing adoption of precision medicine, increasing focus on biomarker-based studies, rising use of artificial intelligence in trial design, expanding pipeline of neurology drugs, and increasing government support and funding for neurological research. Major trends in the forecast period include advancement in neuroimaging technologies, advanced data analytics for patient stratification, development of adaptive trial designs, innovation in wearable neurological monitoring devices, and development of decentralized clinical trial models.
Get your free report sample today:
Which Factors Are Contributing Most to the Expansion of the Neurology Clinical Trials Market?
The increasing prevalence of neurological disorders is expected to propel the growth of the neurology clinical trials market going forward. Neurological disorders refer to conditions that affect the brain, spinal cord, or nerves, impairing the nervous system's normal function. Neurological disorders are increasing primarily due to the aging population, as older adults are more susceptible to age-related conditions such as Alzheimer's and Parkinson's disease. Neurology clinical trials help in neurological disorders by testing new treatments, drugs, or interventions to improve diagnosis, manage symptoms, slow disease progression, and enhance patient outcomes. For instance, in September 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, the number of Australians living with dementia is expected to more than double, increasing from 411,100 in 2023 to 849,300 by 2058. Additionally, by 2058, an estimated 315,500 men and 533,800 women will be living with dementia. Therefore, the increasing prevalence of neurological disorders is driving the growth of the neurology clinical trials market.
Which Key Segments Are Included in the Neurology Clinical Trials Market Analysis?
The neurology clinical trials market covered in this report is segmented –
1) By Phase: Phase I, Phase II, Phase III, Phase IV
2) By Study Design: Interventional, Observational, Expanded Access
3) By Indication: Epilepsy, Parkinson’s Disease (PD), Huntington’s Disease, Stroke, Traumatic Brain Injury (TBI), Amyotrophic Lateral Sclerosis (ALS), Muscle Regeneration, Other Indications
4) By End-User: Hospitals, Clinics, Research Institutes, Other End- Users
Subsegments:
1) By Phase I: Drug Safety Evaluation, Pharmacokinetics Assessment, Dosage Range Finding, Tolerability Studies
2) By Phase II: Efficacy Evaluation, Dose Response Studies, Therapeutic Effectiveness, Biomarker Identification
3) By Phase III: Large Scale Efficacy Studies, Safety Monitoring, Comparative Effectiveness, Risk Benefit Analysis
4) By Phase IV: Post Marketing Surveillance, Long Term Safety Follow Up, Real World Evidence Collection, Quality Of Life Assessment
What Are the Key Industry Trends Driving Growth in the Neurology Clinical Trials Market?
Major companies operating in the neurology clinical trials market, focusing on developing innovative solutions such as monoclonal antibodies to target specific neurological pathways, improve treatment efficacy, and accelerate the development of novel therapies. Monoclonal antibody refers to a laboratory-produced molecule engineered to recognize and bind to specific proteins or antigens, often used to target disease mechanisms with high precision in treatments and diagnostics. For instance, in July 2024, Eli Lilly and Company, a U.S.-based pharmaceutical company, launched Kisunla (donanemab-azbt) for the treatment of early symptomatic Alzheimer's disease. That slows cognitive and functional decline, allowing eligible patients more time to remain independent and participate in daily life. It targets and reduces brain amyloid plaques, with clinical trials showing up to a 35% slowing of disease progression versus placebo in those with less advanced disease.
Who Are the Top Industry Players Driving the Neurology Clinical Trials Market Growth?
Major companies operating in the neurology clinical trials market are AbbVie Inc., Sanofi S.A., Novartis AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., IQVIA Holdings Inc., Biogen Inc., ICON plc., Syneos Health, Charles River Laboratories International Inc., Parexel International Corporation, CMIC Holdings Co. Ltd., Medpace Holdings Inc., PSI CRO AG., Supernus Pharmaceuticals Inc., Worldwide Clinical Trials LLC., Ergomed plc., Biotrial S.A.S., Clinilabs Drug Development Corporation, Lindus Health Ltd.
Get the detailed neurology clinical trials market report today
Which Regional Markets Offer the Most Promising Growth Opportunities for the Neurology Clinical Trials Market?
North America was the largest region in the neurology clinical trials market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurology clinical trials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment